查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614194

内分泌药物市场：依治疗领域、通路划分 - 全球预测 2025-2030 年

Endocrinology Drugs Market by Therapy Area (Diabetes Drugs, Human Growth Hormone, Thyroid Hormone Disorders), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年内分泌药物市值为327.8亿美元，预计2024年将达到350.5亿美元，复合年增长率为7.34%，到2030年将达到538.5亿美元。

内分泌药物市场包括治疗与内分泌系统相关的疾病的药物，例如糖尿病、甲状腺疾病和荷尔蒙失衡。受人口老化、肥胖率上升和生活方式改变等因素影响，这些疾病在全球日益流行，推动了对内分泌药物的需求。这些药物可应用于荷尔蒙补充疗法、血糖调节、代谢疾病管理等，为医院、诊所和个别患者等最终用户提供服务。市场成长主要是由生物技术、个人化医疗的进步以及创新药物输送系统的不断采用所推动的。新的发展机会包括开发针对特定荷尔蒙途径的新型化合物以及提高患者对数位健康解决方案的依从性。然而，市场面临高昂的研发成本、严格的法律规范以及与荷尔蒙疗法相关的潜在副作用等限制，这可能会阻碍成长。还有其他问题，例如与学名药的竞争以及由于成本限製而在发展中地区使用的限制。有前景的创新领域包括探索非侵入性输送系统、优化生物相似药以及利用人工智慧获得精准医学见解。此外，製药公司和研究机构之间的合作可以促进荷尔蒙相关病理学的新发现。在一个以技术快速进步和不断变化的医疗保健需求为特征的市场中，相关人员需要保持资讯灵通和敏捷，强调必须采取适应性策略来满足消费者和监管机构的需求。公司应优先考虑解决广泛的未满足临床需求的研究阶段投资，并探索成分和技术许可合作伙伴关係以加快上市时间。竞争格局凸显了策略併购的重要性，这使得企业能够扩大产品系列和区域格局。总之，对临床试验管道和新兴法规的持续监控对于抓住内分泌药物市场的机会和克服挑战至关重要。

主要市场统计
基准年[2023] 327.8亿美元
预计年份 [2024] 350.5亿美元
预测年份 [2030] 538.5亿美元
复合年增长率（%） 7.34%

市场动态：快速发展的内分泌药物市场的关键市场洞察

供需的动态交互作用正在改变内分泌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 内分泌疾病盛行率增加
    • 提高对内分泌疾病及其管理的认识
    • 人口老化的增加和生活方式的改变导致内分泌疾病的增加
  • 市场限制因素
    • 内分泌药物研发高成本
  • 市场机会
    • 日益关注个人化医疗和标靶治疗
    • 生物技术的进步促进新治疗方法的开发
  • 市场挑战
    • 药品核准严格监理要求

波特五力：驾驭内分泌药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解内分泌药物市场的外部影响

外部宏观环境因素对内分泌药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解内分泌药物市场竞争状况

对内分泌药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵内分泌药物市场供应商的绩效评估

FPNV 定位矩阵是评估内分泌药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划内分泌药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，内分泌药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 内分泌疾病盛行率增加
      • 提高对内分泌疾病及其管理的认识
      • 人口老化和生活方式的改变导致内分泌疾病的增加。
    • 抑制因素
      • 内分泌药物的研发成本较高。
    • 机会
      • 日益关注个人化医疗和标靶治疗
      • 生物技术的进步促进新治疗方法的开发
    • 任务
      • 药品核准严格监理要求
  • 市场区隔分析
    • 治疗领域：随着全球糖尿病盛行率的增加，内分泌药物的研发正在加速。
    • 通路：由于送货上门的便利性，网路药局变得越来越重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗领域分類的内分泌药物市场

  • 糖尿病药物
  • 人体生长荷尔蒙
  • 甲状腺激素失调

第七章 内分泌药物市场：依分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第八章北美和南美内分泌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区内分泌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲内分泌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Alexion 透过收购 Amorit Pharma 加强罕见内分泌产品组合
    • 礼来公司 (Eli Lilly) 的 Munjaro 将在印度上市
    • 诺和诺德收购不变钢 Pharma 以扩大肥胖和糖尿病治疗产品组合
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Ascendis Pharma AS
  • AstraZeneca PLC
  • Bayer AG
  • Beta Cell NV
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hanmi Pharm Co., Ltd.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • MacroGenics, Inc.
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Pfizer Inc.
  • Precigen, Inc.
  • Sanofi SA
  • Shenzhen Microchip Biotechnology Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market was valued at USD 32.78 billion in 2023, expected to reach USD 35.05 billion in 2024, and is projected to grow at a CAGR of 7.34%, to USD 53.85 billion by 2030.

The endocrinology drugs market encompasses pharmaceuticals designed to treat disorders related to the endocrine system, including diabetes, thyroid diseases, and hormonal imbalances. The necessity for endocrinology drugs is driven by the increasing prevalence of these conditions globally, influenced by factors such as aging populations, rising obesity rates, and lifestyle changes. These drugs are applied in hormone replacement therapies, glucose regulation, and metabolic disease management, serving end-users like hospitals, clinics, and individual patients. Market growth is significantly driven by advancements in biotechnology, personalized medicine, and the increasing adoption of innovative drug delivery systems. Emerging opportunities include the development of novel compounds targeting specific hormone pathways and enhancing patient compliance through digital health solutions. However, the market faces limitations such as high R&D costs, stringent regulatory frameworks, and potential side effects associated with hormonal therapies that may hinder growth. Challenges also include competition from generic drugs and limited accessibility in developing regions due to cost constraints. Innovation areas with promising potential include researching non-invasive delivery systems, optimizing biosimilars, and leveraging artificial intelligence for precision medicine insights. Moreover, collaborations between pharmaceutical companies and research institutions can foster new discoveries in hormone-related pathologies. The market, characterized by rapid technological advancements and evolving healthcare demands, requires stakeholders to stay informed and agile, emphasizing adaptive strategies to address both consumer and regulatory needs. Companies should prioritize investment in research phases that address prevalent unmet clinical needs and explore partnerships for ingredient or technology licensing to expedite time-to-market. The competitive landscape underscores the importance of strategic mergers and acquisitions, enabling firms to expand product portfolios and geographic reach. In conclusion, continuous monitoring of clinical trial pipelines and emerging regulations will be crucial for seizing opportunities and navigating challenges in the endocrinology drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 32.78 billion
Estimated Year [2024] USD 35.05 billion
Forecast Year [2030] USD 53.85 billion
CAGR (%) 7.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endocrinology Drugs Market

The Endocrinology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of endocrine disorders
    • Growing awareness about endocrine disorders and their management
    • Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
  • Market Restraints
    • High cost associated with research and development of endocrinology drugs
  • Market Opportunities
    • Increasing focus on personalized medicine and targeted therapies
    • Advancements in biotechnology for the development of novel therapeutic options
  • Market Challenges
    • Stringent regulatory requirements for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Endocrinology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endocrinology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endocrinology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endocrinology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endocrinology Drugs Market

A detailed market share analysis in the Endocrinology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endocrinology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endocrinology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endocrinology Drugs Market

A strategic analysis of the Endocrinology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endocrinology Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ascendis Pharma AS, AstraZeneca PLC, Bayer AG, Beta Cell NV, Biocon Limited, Eli Lilly and Company, Endo International PLC, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co., Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., MacroGenics, Inc., MannKind Corporation, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Precigen, Inc., Sanofi S.A., Shenzhen Microchip Biotechnology Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endocrinology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Area, market is studied across Diabetes Drugs, Human Growth Hormone, and Thyroid Hormone Disorders.
  • Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of endocrine disorders
      • 5.1.1.2. Growing awareness about endocrine disorders and their management
      • 5.1.1.3. Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with research and development of endocrinology drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine and targeted therapies
      • 5.1.3.2. Advancements in biotechnology for the development of novel therapeutic options
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for drug approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Area: Growing prevalence of diabetes across the globe accelerating research & development of endocrinology drugs
    • 5.2.2. Distribution Channel: Increasing significance of online pharmacies due to ease of home delivery
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endocrinology Drugs Market, by Therapy Area

  • 6.1. Introduction
  • 6.2. Diabetes Drugs
  • 6.3. Human Growth Hormone
  • 6.4. Thyroid Hormone Disorders

7. Endocrinology Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital pharmacies
  • 7.3. Online pharmacies
  • 7.4. Retail pharmacies

8. Americas Endocrinology Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Endocrinology Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Endocrinology Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Alexion to Bolster Rare Endocrinology Portfolio with Amolyt Pharma Acquisition
    • 11.3.2. Anticipated Launch of Eli Lilly's Mounjaro in India
    • 11.3.3. Novo Nordisk Acquires Inversago Pharma to Expand Obesity and Diabetes Treatment Portfolio
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Ascendis Pharma AS
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Beta Cell NV
  • 7. Biocon Limited
  • 8. Eli Lilly and Company
  • 9. Endo International PLC
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Hanmi Pharm Co., Ltd.
  • 13. Ipsen Pharma
  • 14. Johnson & Johnson Services, Inc.
  • 15. MacroGenics, Inc.
  • 16. MannKind Corporation
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Novo Nordisk A/S
  • 20. Oramed Pharmaceuticals
  • 21. Pfizer Inc.
  • 22. Precigen, Inc.
  • 23. Sanofi S.A.
  • 24. Shenzhen Microchip Biotechnology Co., Ltd.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ENDOCRINOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOCRINOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOCRINOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID HORMONE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023